Waltz Health, whose search tool helps patients compare drug prices across marketplaces and pharmacies, emerges from stealth with a $35.4M Series A led by GV
Katie Jennings / Forbes :
Context & Ripple Effects
Waltz Health is coming out of stealth with a $35.4M Series A led by GV, betting that drug pricing — not just hospital pricing — is ready for a consumer-facing comparison layer. The move lands two weeks before Turquoise Health's $20M Series A for hospital procedure price search, marking a coordinated wave of transparency startups attacking opaque healthcare costs from both the pharmacy and hospital sides.
The bet ages well: three years later, pharma commercialization firm Eversana merges with Waltz Health in a deal valuing the combined entity at $6B — a steep climb from this Series A, and validation that price-comparison software for insurers became strategic infrastructure rather than a niche consumer tool.
First-order effects
- Waltz gains the capital to scale its cross-marketplace drug price search beyond stealth, with GV's backing signaling investor appetite for pharmacy transparency plays.
- Patients comparing drug prices across pharmacies and marketplaces get a dedicated search tool, and the insurers Waltz targets gain a new procurement lever.
Second-order effects
- Pharmacy-benefits navigators like Rightway, whose app steers employees through digital care and pharmacy benefits, now face a rival whose core pitch is price comparison itself rather than navigation around existing benefits.
- The success of drug price search pressures pharmacy marketplaces and benefit managers to compete on visible pricing, since Waltz's tool makes cross-vendor spreads legible to buyers.
Third-order effects
- The Eversana merger points toward transparency software consolidating into full-stack pharma commercialization platforms, where price comparison becomes one module inside entities that also move the drugs.
- If drug and hospital price comparison keep attracting capital and acquirers, opaque pricing shifts from a competitive moat to a compliance liability across US healthcare.
The trend: Healthcare price transparency is expanding from hospital procedures to pharmaceuticals, with venture-backed search tools graduating into acquisition targets for larger healthcare platforms.